You are currently viewing Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug Discrimination Assay

TORONTO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that its lead candidate, MSP-1014, was comparable to psilocybin assessed using a drug discrimination assay. The results suggest that MSP-1014 induces a similar perceptual state to psilocybin, further confirming the viability of MSP-1014 as a therapeutic analog of first-generation psilocybin as the Company advances MSP-1014 into the clinic.

“In the drug discrimination assay, MSP-1014 demonstrated a dose dependent and full generalization to a psilocybin discriminative cue in rats,” stated Joseph Araujo, Chief Scientific Officer of Mindset. “Furthermore, we identified an effective dosage of 0.6 mg/kg for subcutaneous administration of MSP-1014 with no detrimental effect on the response rate up to doses of 2 mg/kg. MSP-1014 also showed a dose dependent generalization to a psilocybin cue following the oral route of administration. These results further validate MSP-1014 as an effective second-generation psilocybin-like drug candidate.”

“We continue to perform studies across various preclinical models with MSP-1014 and our library of next generation psychedelic compounds. Our goal is to show the differentiation of our novel drug candidates and build a catalog of translational data as we prepare for human clinical trials,” said James Lanthier, CEO of Mindset.

To watch a video of Mindset’s CEO discussing the announcement in greater detail, please visit: https://youtu.be/tYa3sFjGblY.